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ABSTRACT 
 
In the mammalian ovary, anti-müllerian hormone (AMH) helps maintain the ovarian reserve by 
regulating primordial follicle activation and follicular selection, although its role within the avian 
ovary is unknown. In adult mammals, AMH is primarily produced in granulosa cells of preantral 
and early antral follicles. Similarly, in the hen, the granulosa cells of smaller follicles are the 
predominant source of AMH. AMH importance in mammalian ovarian dynamics suggests AMH 
may have conserved, protective functions within developing follicles in the hen. To better 
understand the role of AMH in avian follicle development, we studied the expression pattern of 
the specific AMH receptor. AMH utilizes the TGF-β/SMAD signaling pathway, including the 
specific Type II receptor, AMHRII. qRT-PCR results indicate that AMHRII mRNA expression, 
as well as that of AMH, are highest (p<0.01) in small follicles (1 mm) and decrease as follicle 
size increases. Dissection of 3-5 mm follicles into ooplasm and granulosa components shows that 
AMHRII mRNA levels are significantly greater in ooplasm than granulosa cells. 
Immunohistochemistry revealed AMHRII staining in the oocyte and granulosa cells. In 
mammals, AMH expression is elevated during periods of reproductive dormancy, possibly 
protecting the ovarian reserve. To assess the expression of AMHRII and AMH during a similar 
state in chickens, we evaluated mRNA expression in a broiler strain and an egg-laying strain of 
hens in different reproductive states. AMH and AMHRII mRNA were significantly higher 
(p<0.05) in non-laying ovaries of broiler hens. In molting (with documented feather loss) and 
non-molting layer hens, AMHRII mRNA was significantly greater (p<0.05) in molting hen 
ovaries. These results suggest AMH may contribute to the intra-follicular bidirectional 
communication between oocyte and granulosa cells, and support a potential role of AMH in 
limiting follicle recruitment in hens. 
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    The Woman Who Thinks She Can 
    If you think you are beaten, you are; 
    If you think you dare not, you don't. 
    If you'd like to win, but you think you can't, 
    It is almost a cinch that you won't. 
    If you think you'll lose, you're lost; 
    For out of the world we find 
    Success begins with a fellow's will 
    It's all in the state of mind. 
    If you think you're outclassed, you are; 
    You've got to think high to rise. 
    You've got to be sure of yourself before 
    You can ever win the prize. 
    Life's battles don't always go 
    To the stronger or faster woman; 
    But sooner or later the woman who wins 
    Is the one who thinks she can! 
 
      - Adapted from Walter D. Wintle 
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CHAPTER I 
REVIEW OF LITERATURE 
I. Introduction 
Successful, efficient reproduction is critical to sustained profitability of animal 
production systems. Although extensive research into reproductive pathways has yielded 
significant insight into the mechanics of this complex system, the cryptic regulation behind this 
intricate network is not fully elucidated. Over the last several decades, extensive research has 
increasingly recognized Anti-Müllerian Hormone (AMH) as an essential regulator of prepubertal 
and adult gonadal growth and function, in addition to its previously known role in sexual 
differentiation during embryonic development.  
Alfred Jost discovered AMH in the late 1940's, calling it "l'hormone inhibitrice" as it was 
originally suspected of inhibiting Müllerian duct development in embryonic males. It was 
subsequently named Müllerian Inhibiting Substance or Factor (MIS, MIF) after 19
th
 century 
comparative anatomist Johannes Peter Müller
1,2
. In addition to müllerian duct regression, AMH 
helps maintain the ovarian reserve, regulates folliculogenesis, and modulates steroidogenesis 
within both gonadal environments. Current research points to AMH action extending beyond the 
local gonads, as several studies reveal hormone action or hormone-receptor colocalization in the 
pituitary
3
, brain
4,5,6
, placenta
7
, uterus
8
, prostate
9
, and lung
10
. Additionally, AMH has recently 
grown in importance in regards to human and animal health, due to its diagnostic uses for in vitro 
fertilization techniques
11,12,13,14,15
, granulosa cell neoplasia
16,17,18,19,20
 and evaluating the ovarian 
reserve
21,22,23,24
, as well as for its suspected roles in endometriosis
8,25
 and polycystic ovary 
syndrome
26,27,28,29
. 
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II. Mammalian AMH 
Location and Structure of AMH Gene in Mammals 
 First sourced from newborn calf testes
30
, a 2.1-kb cDNA fragment encoding AMH was 
cloned and purified. The gene structure and sequence of AMH resembled that of other growth 
factors or inhibitors
31
, leading researchers to incorporate AMH into the large Transforming 
Growth Factor-β (TGF-β) family31,32. Early analysis revealed AMH to be a disulfide-bonded32 
homodimeric glycoprotein with lectin affinity
33
. Evidence suggested multiple forms of the 
hormone existed, as molecular weights ranged from 12.5-57 kDa
31
 to 70-74 kDa
30
 to 120-300 
kDa
33
 depending on fractionation technique
34,35
. The human AMH precursor gene is located on 
chromosome 19 (NCBI: NC_000019.10 (2249114..2252073)) and is five exons long with 71% 
GC content across introns and exons. The first 25 nucleotides encode a signal peptide that is not 
well-conserved across species. The human and mouse genes encoding the AMH precursor form 
are 560 and 555 amino acids, respectively, and are relatively conserved (72%) across the entire 
peptide. In non-mammals, such as the zebrafish and the hen, AMH precursor sequence homology 
drops to 41% and 47%, respectively, compared to human. To date, AMH or an AMH homologue 
has not yet been identified in organisms outside of the phylum Chordata. 
AMH Expression and Involvement During Embryogenesis 
 During mammalian embryogenesis, fetal testes produce large quantities of AMH, which 
helps facilitate sexual differentiation in males by regressing the müllerian or paramesonephric 
duct, the precursor tissue that forms the uterus, oviducts, and cranial vagina in females
32,36
. AMH 
RNA and protein have been detected within the rough endoplasmic reticulum and golgi 
apparatus
37
 in cytoplasm of immature Sertoli cells
38
 in fetal or early prepubertal calves
30,32,37,39
, 
sheep, goats, pigs, humans, rats
36,40,41
, rabbits, cats, and chicks. In situ hybridization (ISH) also 
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showed positive AMH signal in spermatocytes
41
. AMH mRNA expression has been identified in 
rat and mouse tissue along the urogenital ridges and within testes as early as embryonic day 15
42
, 
and 12.5 dpc
40
, respectively. On embryonic day 16 in the male rat, AMH mRNA visualized 
using ISH was present surrounding the müllerian duct
42
, which undergoes subsequent regression 
through embryonic day 19
43
. During regression, lysosomes enter the targeted cells, followed by 
macrophagic activity. Subsequent characteristic whorled patterns arise within the degenerating 
müllerian duct as the extracellular matrix degrades
44,45
. Similar timing was observed in vivo 
during regression within Chinese hamster ovary (CHO) cells transfected with recombinant-
human AMH (rhAMH)
30
. AMH transplantation via renal capsules into nude mice also 
successfully regressed the müllerian duct
46
. AMH testicular production decreases postnatally 
throughout the prepubertal period
40,47
 with low but discernible levels found in adult testes
48,49,50
. 
In the mammalian female, biological activity of AMH is generally accepted as absent at 
the embryonic stage in most species evaluated
32,36,40,51
. Exogenous AMH introduced in vivo and 
in vitro to embryonic females resulted in several reproductive abnormalities. Freemartinism, a 
physiological condition that occurs within females when male and female fetuses connect via 
anastomosis
52,53
, is typically characterized by masculinized, smaller ovaries and potential 
seminiferous tubule or sex-cord development
47,52,54,55
. The predominant cause of freemartinism is 
considered to be vascular introduction of AMH produced by the male fetal testes
56
. Serum from 
freemartins also revealed higher AMH levels
57
 than normal females, and freemartin gonads 
produced much less AMH than their male counterparts
56
. Additionally, the freemartin female 
becomes chimeric, and some chimeric cells within freemartin gonads express AMH protein
58,59
. 
Physiologically normal male and female fetuses have been observed if joint vascularization fails 
to occur, providing additional support that AMH is the causative factor
60,61
. 
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Seemingly related to placentation type, a freemartin female can occur if a chorion is 
vascularly shared with a male fetus between 50 and 80 days gestation (in bovine)
56,60
. 
Freemartins have been primarily reported in bovine
59,61
 and ovine
62
 fetuses, and can exhibit a 
wide scale of reproductive anomalies
59,63
. Some freemartin females form intermediate or 
intersex
58
 gonads, while others develop smaller, masculinized ovaries or small, under-developed 
testes
62
. Steroidogenesis (i.e. estrogen production, etc.) in the freemartin ovary is also affected 
accordingly
61,64
. 
In addition to those effects witnessed in natural and induced
64
 freemartins, germ cell 
depletion occurred in vitro when fetal rat ovaries were cultured with bovine AMH
54
. However, 
naturally-occurring AMH with observable bioactivity during female mammalian embryogenic 
development has been reported. Researchers detected AMH protein expression within embryonic 
ovine ovaries beginning at 120 days gestation, concomitant with observed follicular 
development
65
. In sheep, production of AMH late in gestation is unlikely to interfere with sexual 
differentiation, which occurs between days 30 and 85 gestation in fetal sheep
66
. Granulosa cells 
from preantral follicles displayed faint AMH immunoreactivity, parallel to results observed in 
granulosa cells of prepubertal and adult females.  
AMH Expression in Adult Female Mammals 
The postnatal bioactivity of AMH in female mammals is well documented. The presence 
and production of AMH coincides with follicular growth. Observations suggest AMH production 
within granulosa cells corresponds with increased follicular development, as strong ISH signal 
was seen from growing small preantral and antral follicles of mice
40
, sheep
65
 and cows
67
, and 
within primordial follicles in primates
68
. AMH RNA or protein expression has been repeatedly 
detected in cytoplasm of granulosa cells in prepubertal and adult females
42,33,36
, as early as three 
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and six days postpartum in the rat
36
 and mouse
40
, respectively. It should be noted that AMH has 
been localized via in situ hybridization and IHC within rat
69
 and caprine
209
 follicles, respectively. 
A signal gradient has occasionally been observed within the granulosa cell layer, with intensity 
highest in cells nearest the antrum
40,65,70
 of larger follicles, while homogenous AMH 
distribution
36
 throughout the granulosa cell layer has also been reported. This potential gradient 
towards the oocyte occurred alongside AMH secretion into follicular fluid within the antrum, 
suggesting AMH could have biological functions within developing follicles
71,72
. In adult 
females, AMH production continues during folliculogenesis into the pre-ovulatory phase
73,74
, and 
steadily declines overall as the ovarian reserve diminishes until menopause
21,24
. 
AMH-null Mouse Model 
 AMH-deficient mice were developed to better understand the specific role of AMH in 
vivo. A neomycin resistance expression cassette was inserted via electroporation into embryonic 
mouse stem cells, replacing 0.6-kb of the mouse AMH gene (part of Exon 1, and all of Intron 1 
and Exon 2)
75
. These mutant stem cells were then injected into C57BL/6J mice wild-type, which 
were then bred to B6/129 wild-type mice to generate chimeras
75
. To evaluate dosage response of 
AMH, AMH heterozygous (AMH
+/-
) mice were bred in addition to AMH null (AMH
-/-
) mice. 
Southern blot DNA analysis validated the successful transfection, showing a band corresponding 
with AMH present in wild-type and AMH
+/-
 mice, and a band for the inserted neomycin cassette 
in both the AMH
+/-
 and AMH
-/-
 mice. 
 While AMH
+/-
 males were morphologically normal and capable of fathering pups
75
, 
AMH
-/-
 males expectedly developed components of the female reproductive tract: the müllerian 
duct developed into a partial vagina, cervix, uterus and oviducts
21
. This morphology, termed 
Persistent Müllerian Duct Syndrome (PMDS), characterized by retained müllerian-derived 
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tissues that develop alongside normal male tissues, has been infrequently reported in human 
males. Additionally, Leydig hyperplasia was occasionally observed in AMH
-/-
 males, with one 
observation of Leydig neoplasia. 
 A dosage effect observed in AMH transgenic males revealed AMH
-/-
 males had 
azoospermia and therefore reduced fertility when compared to AMH
+/-
 and wild-type males. 
However, spermatogenesis did not appear to be affected, as sperm collected from the 
epididymides of AMH
-/-
 males were able to successfully fertilize wild-type embryos via IVF and 
produce pups
75
. Researchers concluded that AMH was not necessary for male germ cell 
development, theorizing successful fertilization was physically blocked due to the presence of 
additional female organs and structures. Infertility was reversed when a transgene chronically 
overexpressing human AMH was inserted into AMH
-/-
 males. Additionally, the majority of these 
AMH
-/-
 males exhibited no müllerian duct-derived tissue following the procedure
76
. 
 Female AMH transgenic mice were also affected. AMH
+/-
 females were viable, fertile 
and phenotypically normal
75
. AMH
-/-
 females displayed morphologically normal reproductive 
tracts, with granulosa cells of comparable quantity and histological properties relative to AMH
+/-
 
and wild-type females. However, folliculogenesis in AMH transgenic mice was significantly 
altered. AMH
+/-
 and AMH
-/-
 female mice were analyzed relative to age-matched wild-type 
mice
21
. In prepubertal females, no significant difference was found between primordial follicle 
populations of AMH
-/-
 and AMH
+/+
 mice, but 4- and 13-month old AMH
-/-
 mice had significantly 
fewer remaining primordial follicles than their wild-type counterparts
21
. Females exhibited an 
AMH dosage effect, and AMH
+/-
 females had an ovarian reserve of intermediate size among the 
genotypes
21
. Serum inhibin and FSH levels corresponded with progressive follicular 
development in AMH
-/-
 females relative to wild-type females: inhibin was two-fold higher and 
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lower in 4- and 13-month old AMH
-/-
 females, respectively, and FSH was lower in 4-month old 
AMH
-/-
 females. All three groups exhibited regular estrous cycles of equivalent length and 
comparable numbers of corpora lutea
21
. Uterine weight was also similar among genotypes. 
Further analysis to explain the relatively equal number of corpora lutea revealed increased atresia 
and oocyte degeneration in non-wild-type females
77
. 
Mouse Model Overexpressing AMH 
A mouse model chronically overexpressing AMH was designed to help characterize the 
in vivo role of AMH during embryonic sexual development. The metallothionein-1 promoter 
joined to the human AMH gene was introduced via pronuclear injection
76
. Male and female 
transgenic mice showed reproductive abnormalities of varying severity, attributed to germ-line 
mosaics producing varying AMH serum concentrations. Two sterile founder females lacked 
ovaries, oviducts and uteri, but founder males were fertile
76
. However, female offspring from 
those founder males continued to exhibit morphological deformities similar to the founding 
females. Ovaries were present in females with lower AMH serum concentrations. Female 
offspring from the mouse line with the highest AMH serum concentration were evaluated 
throughout different developmental stages to temporally chronicle changes in reproductive 
tissues. Two days after birth, no uteri were observed, and ovaries, although present, contained 
fewer germ cells than controls. By nine days postpartum, no follicles were present and zero germ 
cells remained. While the gonads had by this time developed structures analogous to 
seminiferous tubules, no gonadal structures remained by adulthood in female transgenic mice
76
. 
Some of the male offspring chronically expressing high AMH serum concentrations 
displayed reproductive abnormalities as well. Several males exhibited broad signs of 
feminization, including mammary gland development and a vaginal opening
76
, as well as 
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undescended testes lacking a germ cell population, and poorly developed accessory male tissues. 
Based on these results, researchers hypothesized AMH might help regulate Leydig cell 
development and function by reducing androgen production. 
AMH transgenic male mice exhibit physiological anomalies apart from changes within 
reproductive tissues. In addition to its direct effects on the müllerian duct, AMH is believed to 
contribute to systemic sexual differentiation beyond the local testes
5,78
. Researchers hypothesized 
AMH exerts sex-dependent, neuronal influences to varying degrees based on systemic AMH 
circulation during embryonic and early prepubertal development
5,79,80
. Circulating AMH levels 
can be sexually dimorphic: AMH serum levels in young boys have reported as highly 
variable
81,82
, yet were quite consistent in young girls
81
. Androgen-dependent, neuronal 
masculinization during development has already been established across multiple species, though 
the contributions of AMH during this process are still cryptic
66,83,84
. 
AMH Involvement in Non-reproductive Mammalian Tissues 
AMH protein has also be identified in neurons, and has since been shown to be potent 
survival factor in vitro for cultured lateral motor column (LMC) neurons
4,78,85
. A gender-based 
phenomenon has been observed in mouse neurons: AMH
-/-
 male mice develop less LMC neurons 
than wild-type males
5
, while comparable neuron counts were found between AMH
-/-
 males and 
wild-type females. Evaluations of newborn (D 0) AMH transgenic mice from the original AMH 
transgenic mouse colony revealed LMC neuron quantity decreased significantly per AMH copy 
removed. AMH
+/-
 and AMH
-/-
 males contained intermediate and feminized numbers of motor 
neurons, respectively
5
. Wild-type females had significantly fewer LMC neurons than wild-type 
males
5
. Similarly, sex-biased expression was observed in calbindin-positive (CP) neurons in 
prepubertal wild-type mice with increased CP neuron quantities in males, but the sex-bias was 
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absent within AMH
-/-
 prepubertal mice
85
. However, adult AMH
-/-
 males developed additional CP 
neurons as they aged, though wild-type quantities were not restored. 
In addition to local and systemic sexual differentiation, AMH may have roles within 
several other tissues, including the prostate
9
, placenta
7
 and uterus
8
. A more well understood role 
of AMH is within the immature embryonic lung, where AMH has been shown to negatively 
affect embryonic lung maturation in males
86,87
. Mouse embryonic lung tissues were investigated 
in vitro, due to their spatial proximity to the urogenital ridge from 13.5 dpc through 15 dpc
10
. 
Embryonic lung tissues (13.5 dpc) cultured with two different rhAMH concentrations both 
exhibited significantly less lung development compared to control and vehicle buffer culture 
mediums
10
. Observations included fewer lung bud counts, decreased explanted lung perimeter 
length (i.e. branching) and increased apoptosis. These in vivo effects provide morphological and 
histological details supporting sex-dependent embryonic lung development and maturation.  
AMH Biochemistry and Signaling Pathway 
While AMH affects multiple tissues across the body, its employs a consistent 
biochemical mechanism of action to exert biological influence. Akin to other TGF-β family 
members, AMH elicits cellular changes via a SMAD signaling pathway. Secreted as a 140 
kDA
30
 homodimeric glycoprotein, specific proteolytic cleavage must first occur to ensure 
efficient bioactivity and receptor reactivity
88
. In humans, cleavage of the AMH precursor 
(proAMH) occurs at 109 amino acids upstream from the carboxyl terminus, forming two 25 kDA 
C-terminus dimers
89
. Subtilisin/kexin-type proprotein convertases (PCSKs) or serine proteases 
can facilitate initial proteolytic cleavage of proAMH
89,90
. However, AMH undergoes a 
variation
88,91
 of cleavage different than TGF-β: the 70 kDA N-terminus (pro-region) of AMH 
remains connected to the 25 kDA C-terminus dimer, forming a noncovalent complex (AMHN,C) 
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that subsequently binds a receptor then dissociates
91
. BMP-7
92
 and BMP-9
93
 utilize similar 
dimerization, but other TGF-β family members88, including TGF-β, GDF-8 and BMP-2, require 
the noncovalent complex to first dissociate prior to receptor binding
91
. 
Bioactivity of AMH varies based on cleavage locations and dimerization. While AMHN,C 
has been shown to have the greatest bioactivity of the AMH forms, proAMH is still bioactive, 
but to a much lesser extent
91
. In the blood, proAMH is not easily cleaved by proteases
94
, but 
evidence exists demonstrating some enzymes locally accessible or native to the target tissue can 
and do cleave AMH, increasing AMHN,C concentration at the target site
95,96
. Researchers have 
shown proAMH is the primary AMH biochemical species within ovine follicular fluid and 
granulosa cell
97
 cytoplasm and nuceli
98
. Both proAMH and AMHN,C are found in adult human 
serum, but AMHN,C is the predominant form
99
. The half-life of rhAMH, evaluated using rh-
proAMH and rh AMHN,C injected into mice, were quantified using a two-phase elimination 
curve. The assay solely measured the rhAMH, not the mouse AMH native to the animals. In the 
slow phase, the half-lives for rh-proAMH and rhAMHN,C in mice were 2.4 and 3.8 hours, 
respectively, while the fast-phase half-lives were 6 minutes and 11 minutes, respectively
94
. The 
half life of AMH in other species, including calves
100
 and women
101
, has been reported at 
approximately two days and just over one day, respectively, with castrations and hysterectomies 
immediately preceding the half-life evaluations.  
Additionally, in vivo AMH protein variations have been identified. Three human AMH 
splice isoforms have been documented, but their biological activity and relevance have not yet 
been characterized. Several variations or mutations exist within the human AMH promoter 
region or whole gene that severely limit AMH bioreactivity
102,103
, while other mutations do not 
appear to elicit a change of function
104
. AMH dimerization capabilities or proper transcription 
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factor signaling are likely reduced in loss-of-function cases. Furthermore, studies focused on 
determining AMH serum concentrations have been hampered by challenging assays. Precisely 
analyzing accurate AMH concentrations in serum has been difficult due to inclusion or exclusion 
of the cleaved-yet-associated forms of AMH. These complications
105
 contributed to the impaired 
sensitivity and repeatability throughout several assay generations and 
modifications
106,107,108,109,110,111
, at times imparting dubious biases
112,113,114
, but newly updated 
assays equipped to handle these technicalities are being incorporated into research protocols. 
Also, the various cleaved forms of AMH can now be studied separately or in combination to 
better elucidate its mechanism of action
115
. 
Once cleaved, AMH utilizes two TGF-β serine-threonine domain receptors116,117. First, 
AMH binds to the extracellular portion of its specific
118
 primary receptor, AMH Type II 
Receptor (AMHRII), which subsequently phosphorylates one of three non-specific Type I 
receptors: ALK2/ACVR1
119,120
, ALK3/BMPR1A
121,122
 or ALK6/BMPR1B
123
. Once AMH binds 
both TGF-β receptors, the AMH-receptor complex triggers the SMAD signaling cascade, 
phosphorylating three receptor-regulated Smads (R-Smads) within the cellular cytoplasm: 
Smad1, Smad5 and Smad8
20,123,124,125,126
. The three activated R-Smads then complex with 
common-mediator Smad4, stimulating active transcription factor formation within the nucleus
127
. 
Type I receptor recruitment by AMH appears to be target-tissue specific
121
. Regressed 
müllerian ducts in ALK6 null male mice suggest localized redundant or tissue-specific 
receptors
120
; indeed, ALK2 has been shown to compensate in ALK6 null males
120,124
. 
Researchers determined ALK3 is also required for müllerian duct regression
128
. Preferential 
phosphorylation of candidate secondary receptors also exists within granulosa and Leydig cells, 
observed during ALK3 knock-down experiments in mice. Granulosa cells from prepubertal 
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ALK3 knock-down mice were unresponsive to AMH
122
, and steroidogenesis decreased within 
Leydig cells, leading to plasma androgen levels equivalent to control mice
121
.  
Regulation of AMH in Mammals 
AMH regulation in mammals has not been fully elucidated. The human AMH promoter, 
first thought to be well under 450 bp in length, has since been determined to be considerably 
longer. Experiments conducted utilizing 202-, 423-, and 3-kb length human AMH promoters 
within SMAT1 Sertoli cell lines incubated with cAMP revealed significantly greater luciferase 
activity with the 3-kb promoter, suggesting additional transcription factor binding sites exist 
farther upstream than originally suspected
129
. Several binding sites identified within the human 
AMH promoter have been evaluated for their potential roles in transcription and mechanism of 
action of AMH. SRY, a master sex-specific gene underlying the male sex-determination cascade, 
binds to a site -145 bp upstream of the AMH transcription start site
130,131,132
. In the embryonic 
testis, SRY mRNA production begins approximately 10.5 dpc in the mouse
133
, declining shortly 
after 12 dpc until cessation by 13.5 dpc
134
. AMH mRNA transcripts are detectable within a day 
following the initiation of SRY production, and reach and sustain high levels after 12.5 dpc
133
. 
Mutagenesis of the SRY binding site did not eliminate AMH transcription, suggesting SRY may 
influence AMH indirectly
135
. 
SOX9, a second transcription factor important for AMH bioactivity, binds 141 bp 
upstream of the AMH transcription start site. In the testis, cAMP and PKA help facilitate the 
cytoplasmic-to-nuclear translocation of SOX9 protein within Sertoli cells prior to the onset of 
AMH protein expression; in females, this protein repositioning fails to occur
136,137,138
. Corruption 
of the SOX binding site inhibits AMH transcription and müllerian duct regression, leading 
researchers to conclude SOX9 is required for AMH transcription in mammals
103
. However, 
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evidence exists of SOX8 binding in lieu of SOX9, resulting in attenuated AMH transcription 
levels
139,140
. Transgenic mice lacking either SOX8 or SOX9 develop spermatogenesis defects, 
likely caused by the dissolution of the basal lamina
141
, and SOX8
-/-
/SOX9
-/-
 double mutant males 
exhibit signs of feminization, as evidenced by up-regulation of ovarian markers
142
. Within the 
ovary, SOX8 mRNA expression did not colocalize with AMH in granulosa cells of preantral 
follicles, but was instead observed within oocytes
143
. In preovulatory follicles, SOX8 mRNA 
expression was evident in both oocytes and granulosa cells, and was significantly greater in 
mural granulosa compared to cumulus cells.  
Another transcription factor, SF1, acts synergistically alongside SOX8 or SOX9 to 
upregulate AMH transcription
139,144
. Two functional SF1 binding sites have been identified 
within the human AMH promoter at -92 and -218 bp, and AMH and SF1 colocalizes at E12.5 in 
embryonic testes
145,146
. Disruption of one SF1 binding site failed to block müllerian duct 
regression, but AMH transcription was greatly reduced
103
. When both sites were mutated, AMH 
transcription was repressed
145
. Additionally, SF1 exhibits sexually dimorphic expression patterns 
in rats
145,147
. In males, SF1 RNA transcript levels sharply increase parallel to müllerian duct 
regression, while SF1 transcript levels steadily decline in females until parturition
146
. 
SF1 also plays a critical role within the postnatal ovary. Produced in granulosa cells
148,149
, 
SF1 regulates steroidogenesis by helping facilitate cellular cholesterol uptake and 
processing
150,151,152
, and induces transcription via binding to the promoters of CYP19A1
152
, 
CYP11A
153
, oxytocin
154
, prolactin
155
 and StAR
156
, in addition to AMH. SF1
-/-
 female mice 
displayed hemorrhagic ovarian cysts along with sterility
157
. When SF1 production was knocked 
down in granulosa cells, SF1
-/-
 females failed to produce corpora lutea and folliculogenesis was 
significantly reduced
158
. AMH tRNA expression showed a dose-dependent response to SF1: 48 
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hours following eCG treatment, SF1
-/-
 females produced only basal AMH levels, and SF1
+/-
 
females exhibited intermediate AMH levels relative to wild type females
158
. Additionally, 
ovaries from SF1
-/-
 females contained significantly fewer numbers of remaining primordial 
follicles, providing another indication of the importance of SF1 in the AMH pathway. 
Bone morphogenetic proteins (BMP), a TGF-β subfamily, can upregulate AMH promoter 
activity. Several BMP family members, including BMP-2, -6, -7 and -15, have been shown to 
increase AMH mRNA and protein levels within granulosa cells
159,160
. In the presence of BMP-4, 
inclusion of the SF1 and SMAD1 binding regions within the AMH promoter have been shown to 
significantly stimulate AMH transcription versus exclusion of those regions
161
. This evidence 
suggests members of the BMP family may interact with other transcription factors to regulate 
AMH, although the mechanism of action remains unknown. 
Two additional transcription factors, GATA4 and WT1, are capable of working in 
collaboration with
162,163,164
 or independent of
165,166,167
 SF1 to up-regulate AMH transcription. 
Mutations in SF1 prevent synergistic activity with GATA4
168
. The AMH promoter contains two 
GATA regulatory elements at -75 and -168 bp that are necessary for full AMH transcription; 
targeted mutagenesis to either GATA binding site severely impaired or eliminated this 
process
145,167
. In males, GATA4 protein increased within Sertoli cells during embryonic 
development, but decreased in females following ovarian differentiation
167,169
. In the adult ovary, 
GATA4 mRNA, as well as mRNA of family member GATA6, has been located within nuclei of 
granulosa cells in primary and antral follicles, as well as theca cells and other ovarian 
tissue
170,171,172,173
. Ovarian dynamics are severely affected when GATA4 and GATA6 are 
simultaneously silenced, including retained oocyte nests, decreased primordial follicle activation 
and diminished developmental capacity of oocytes concomitant with poor 
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folliculogenesis
174,175,176
. Such observations suggest a level of functional redundancy between 
these two GATA family members; indeed, eliminating either GATA4 or GATA6 did not result 
in such widespread deleterious effects
175
. However, GATA1 can also bind both GATA 
regulatory elements within the AMH promoter, and increases during the onset of meiosis while 
AMH levels decline, suggesting GATA1 may help curtail AMH transcription
177
. 
FOG2, a GATA4 cofactor, is present in the fetal and postnatal ovary. In the embryonic 
testis, FOG2 decreases with sex cord development, suggesting FOG2 may play a greater role 
within the ovary. Indeed, a dosage effect for both FOG2 and GATA4 has been implicated in sex 
reversal in mice
178
. FOG2 protein expression has been found in granulosa and theca 
cells
143,173,179
. While the FOG2-GATA4 complex upregulates SRY
180
 and SOX9
181
 transcription, 
it has been shown to repress AMH transcription in vitro in the presence of GATA4
179
. FOG2 
might therefore modulate the effects of GATA4 activation of AMH within the ovary.  
In men, mutations within the transcription factor WT1 result in retained müllerian duct 
tissue, prompting researchers to analyze the role of WT1 within the AMH pathway. WT1 binds 
to a site within the AMH promoter, increasing AMH transcription
182
. WT1 can coordinate with 
both GATA4 and SF1 to regulate AMH transcription, but if either the GATA4 or WT1 binding 
sites within the AMH promoter are mutated, the synergistic activity is lost
183
. This cooperative 
effort between GATA4 and WT1 also up-regulates SRY
183
. In the ovary, WT1 mRNA 
colocalizes with AMH within granulosa cells, suggesting WT1 likely also regulates AMH 
transcription in females
143
. Additionally, while multiple WT1 isoforms have been identified, 
isoforms lacking the tripeptide KTS yield conflicting effects on AMH transcription
164,165,183
. 
Furthermore, the synergistic complexes formed with SF1 are disrupted by DAX1, allowing for 
negative regulation of AMH transcriptional activation. DAX1 interferes with SF1, reducing the 
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capacity of SF1 to synergize with WT1
164
 or GATA4
184
. DAX1 mRNA colocalizes with SF1 and 
GATA4 within granulosa and Sertoli cells, providing a sex-independent mechanism to modulate 
AMH transcription
143,184
.  
In addition to the sex differentiation genetic pathway, endogenous hormonal factors 
contribute to AMH regulation, although the mechanisms utilized by hormone signaling pathways 
to modify AMH remain unclear. Estradiol functions through two follicular receptors, ERα and 
ERβ, which are predominantly found within thecal and granulosa cells, respectively. Estradiol 
has been shown to influence AMH transcription in vitro through an abridged estrogen response 
element site within the AMH promoter at -1772 bp. When estradiol signals through ERβ, AMH 
transcription declines; however, if estradiol instead utilizes ERα, AMH promoter activity 
increases
185
. This evidence suggests follicular estradiol production may promote folliculogenesis 
by transitioning its effect from boosting to curtailing AMH within developing follicles. 
Additionally, estradiol may only exert an indirect influence on AMH, as the partial estrogen 
binding site within the AMH promoter does not appear to share high affinity with ERβ185. 
Furthermore, the addition of FSH accompanying ERβ in the absence of estradiol yielded more 
than a three-fold increase in AMH promoter activity, yet FSH stifled AMH transcription in the 
presence of ERβ coupled with estradiol185. 
The interaction between FSH and AMH has been evaluated within testicular and ovarian 
dynamics. Within the prepubertal testis, FSH stimulates AMH secretion prior to androgen 
receptor development, suppressing steroidogenesis via reduced aromatase activity by lowering 
aromatase mRNA levels
186,187,188,189,190
. In this manner, AMH temporarily inhibits testosterone 
synthesis
191
. Once Sertoli cells gain functional androgen receptors, intratesticular testosterone 
downregulates AMH, attenuating the stimulatory effect of FSH
192
. Likewise, FSH upregulates 
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AMH transcription within granulosa cells in vitro
193
. To induce these effects, FSH utilizes cAMP 
and the PKA pathway
194
. The 3-kb AMH promoter fails to contain a classical cAMP regulatory 
element (CRE), though two cAMP-responsive sites, NF-κB and AP2, have been identified138,195. 
These two sites work in concert with GATA4 and SF1 to facilitate a response to cAMP 
stimulation (Figure 1.1).  
 The hormonal components of the hypothalamic-pituitary axis have also been implicated 
in AMH regulation. GnRH agonists briefly stimulated then reduced AMH levels in primary and 
antral follicles
196
, and decreased AMH concentrations within follicular fluid
197
. While the 
mechanism GnRH employs to curtail AMH is unknown, GnRH has been shown to decrease 
AMH receptivity
3
. Pregnant rats immunized against GnRH systemically increased AMH in 
offspring
198
. Similarly, growth hormone (GH) treatment reduced AMH serum concentration, but 
the addition of GH-agonist resulted in AMH serum levels comparable with controls
199
. 
Downregulation of AMH by GH may occur through the JAK2/STAT3 signaling pathway. 
Additionally, evidence exists of the metabolic pathway affecting AMH production. In rats, over-
nutrition during gestation or immediately following birth altered AMH secretion and 
folliculogenesis within offspring, but the direct changes that modified AMH are unclear
200
. 
However, leptin is believed to utilize the JAK2/STAT3 pathway to repress levels of AMH 
mRNA in human granulosa cells
201
. Overall, the combined effects of these hormones on AMH 
production and function, as well as their mechanisms of action, are not resolved. 
Downstream Targets of AMH in Mammals 
 The downstream targets of AMH remain largely uncharacterized. Evidence 
indicates AMH-induced müllerian duct regression results from a systematic cascade of events 
culminating in mesenchymal breakdown and ultimately apoptosis. AMH does not appear to  
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Figure 1.1  Adapted from Lasala, et al. 2011
138
. Schematic model to explain the increase of testicular 
AMH production following FSH stimulation. Several transcription factors that bind to the AMH promoter 
are also illustrated. 
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directly stimulate apoptosis within target cells
202
. However, AMH triggers a spatial relocation of 
AMHRII from epithelial to mesenchymal cells via ALK2, accompanied by autocrine regulation 
of the AMH pathway
123
. In mesenchymal cells, AMH suppresses the WNT/β-catenin (CTNNB1) 
pathway, which promotes proper spatial interaction between cells and cellular adhesion, by 
stimulating WIF1, a β-catenin inhibitor203,204. If the WNT/β-catenin pathway is not suppressed, 
the müllerian duct fails to regress. Granulosa cell tumors may develop if the WNT/β-catenin 
pathway is incorrectly regulated
17
. Similarly, AMH also targets another gene, matrix 
metalloproteinase-2 (MMP2), to degrade the extracellular matrix. MMP2 exhibits temporal- and 
male-sex-biased expression similar to AMH. Without AMH, male-biased MMP2 expression 
disappears; MMP2 exclusion impairs müllerian duct regression
205
. 
Within the testis microenvironment, AMH reduces steroidogenic activities within Leydig 
cells by blocking mRNA production and transcription of CYP17A1
190,194
 and decreasing LH 
receptor mRNA
206,191
. As a result, AMH reduces testosterone synthesis
191
. AMH also lessens the 
upregulating effects of cAMP, although the precise interactions between AMH and cAMP in this 
physiological microenvironment are still undetermined
188,207,208
.  
The ovary represents another critical target site for AMH. In many species, one of the 
primary functions of AMH in the ovary is to suppress primordial follicle activation from the 
ovarian reserve
209,210
. AMH can inhibit meiosis within oocytes of some species
211
 but knowledge 
of the mechanism of action in this context is highly limited. A secondary role of AMH is to help 
regulate the development of gonadotropin-dependent follicles. AMH has been shown to reduce 
FSH sensitivity within these follicles
97,212
. Two micro-RNAs, miR-181a and miR-181b, have 
recently been identified as targets of AMH; AMH upregulates these micro-RNAs, reducing intra-
follicular cAMP levels and thus FSH sensitivity
213
. In addition, within granulosa cells, 
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exogenous AMH significantly upregulates expression of ID3, a gene involved in stem cell 
differentiation
122
. A third level of AMH involvement in the ovary targets periods of reproductive 
quiescence. During these times, AMH serum levels often increase, suggesting AMH guards the 
ovarian reserve during times of restricted fertility, further limiting follicular recruitment and 
development
72,214
. To date, the mechanism of action underlying this phenomenon has yet to be 
identified.  
Several non-reproductive pathways and genes are recognized as targets of AMH action. 
Within several cancer cell lines in vitro and within the prostate in vivo, AMH has been shown to 
upregulate IEX-1S, a gene within the NF-κB pathway, stunting cell growth and stimulating 
apoptosis within the cell lines
9,215,216,217
. In the brain, AMH promotes transcription of 
neuroserpin, which targets and inhibits tissue-type plasminogen activator, a compound with 
deleterious effects on brain and nervous tissue function and longevity
6
. In immature female rats 
in vivo, AMH promotes FSH transcription via upregulating Fshb in the pituitary
218
. Within the 
pituitary and neurons, AMH and GnRH interacts in a conflicting manner. While AMH has been 
shown to increase LH secretion from GnRH neurons in mice
4
, exogenous GnRH decreases 
AMHRII protein in the pituitary of female rats
218
. These findings may indicate the presence of a 
negative feedback loop involving gonadotropins and AMH between the gonads and pituitary. 
III. Mammalian AMHRII 
Location and Structure of Mammalian AMHRII 
 AMH requires a specific receptor AMHRII to facilitate its downstream effects. First 
identified in rat testicular tissue, a 1.9-kb cDNA encoding AMHRII was sequenced, which 
revealed several conserved regions characteristic of TGF-β type II receptor proteins, including a 
well-conserved series of serine-threonine kinase domains and cysteine residues
42,219
. In humans, 
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AMHRII is found on chromosome 12 (NCBI: NC_000012.12 (53423855..53431534)) and is 13 
exons long with GC content of approximately 53% across introns and exons. AMHRII is 
comprised of 573 and 568 amino acids in the human and the mouse, respectively, with 81% 
homology between the entire peptides. The first three exons encode a signal peptide and 
extracellular domain, while the fourth and part of the fifth exons represent the transmembrane 
domain; the remaining exons form the intracellular C-terminus. The signal peptide and 
extracellular domains appear to be relatively species-specific, but homology across species 
increases dramatically within the biologically active C-terminus. 
AMHRII Expression in Mammals 
 To date, AMHRII expression strictly occurs in association with concomitant AMH 
expression. Thus, AMHRII has not been observed temporally without impending or current 
utilization by AMH. The aforementioned temporal expression patterns of AMH coincide with 
AMHRII. However, AMH and AMHRII do not inherently share the same spatial expression. In 
embryonic males from E14-E16, AMHRII mRNA and protein are found in mesenchymal tissue 
and surrounds the müllerian duct to facilitate müllerian duct regression
219
. In addition, AMHRII 
has been observed via ISH in both the embryonic male (urogenital ridges) and female (ovary) rat 
on E15-16
42
. Postnatally, AMHRII mRNA is present within Leydig and Sertoli cells, remaining 
even after AMH declines
220,221
. AMH and AMHRII are co-expressed within follicles in 
granulosa cells in females
222
, and also colocalize in GnRH neurons
4
.  
Regulation of AMHRII in Mammals 
The AMH signaling pathway necessitates the mutually inclusive presence of both AMH 
and AMHRII, so the previously mentioned experiments utilizing AMH knockout mice 
theoretically represent the effects of inactivating AMHRII. Regulation of AMHRII is also similar 
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to that of AMH. The AMHRII promoter has been identified as 2252 bp in length, and BMP4 and 
BMP15 have been shown to upregulate AMHRII in both human and sheep granulosa cells
223
. In 
combination with exogenous AMH, c-Jun N-terminal kinase inhibitor II (SP600125), a 
reversible JNK inhibitor, synergistically upregulated AMHRII promoter activity
224
. 
Within a shorter (1136-bp) AMHRII promoter, regulatory sequences corresponding to 
two GATA, one SOX, one SF-1 (estrogen receptor half site), and two SP1 sites were 
identified
225
. The inclusion of binding sites for SF-1, the distal GATA, and SP1 increased 
AMHRII promoter activity, as observed via a luciferase assay
225
. Additionally, SF1 has been 
shown to synergistically upregulate activity of an 863-bp AMHRII promoter when coupled with 
β-catenin and TCF-4 (Transcription Factor 4). Without SF-1, however, β-catenin and TCF-4 still 
activate the AMHRII promoter. Although TCF-4 utilizes four binding sites, mutagenesis of each 
site revealed sites one and four to be functionally critical
226
. Furthermore, recent studies have 
identified a different method of negative regulation of AMHRII. Biological activity of AMHRII 
can be affected by mutations or SNPs within AMHRII
227
, or from significant levels of post-
translational processing
228,229
. These alterations can yield truncated or inactive forms of AMHRII 
with reduced AMH binding capacity, and may contribute to an autocrine manner of regulation of 
AMH and AMHRII. 
IV. Avian AMH and AMHRII 
Location and Structure of AMH in the Chicken 
 Isolated from eight week old chick testes, a 2846-bp cDNA was sequenced and identified 
as AMH. The chicken AMH gene, located on chromosome 28 (NCBI: NC_006115.4 
(2018795..2022986, complement)), is also five exons long but has only a 61% GC content across 
introns and exons. The chicken AMH gene encodes 644 amino acids with a molecular mass of 
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70.6 kDa
230
 or 74kDa
231
; the first twenty amino acids form a signal peptide. Molecular weights 
have been observed on Western blots at approximately 12.5, 72 and 94 kDa
232
. While avian 
AMH is biologically active in mammals, mammalian AMH fails to activate müllerian duct 
regression in avian species
233
, possibly resulting from low homology in the binding region of 
AMH or extracellular region of AMHRII. 
AMH Activity During Avian Embryogenesis 
Similar to mammalian embryology, AMH is produced in the avian testes beginning on 
E4.5-5
230,234,235,236
. Unlike mammals, however, the embryonic chick ovary also produces high 
levels of AMH at the same age, although AMH expression becomes male-biased by E5.5-6
237
. In 
muscovy duck embryos, a similar gene expression shift is observed: AMH mRNA expression 
was significantly higher in males than females on E8-10, and AMH mRNA increased in males 
between E7-10
238
. While AMH facilitates müllerian duct regression in male chicks during E9-13, 
AMH also regresses the right reproductive müllerian duct between E11-14 in females of many 
avian species
239
. In female chick embryos, estrogen binds to estrogen receptors in the cytoplasm 
of the müllerian duct, selectively protecting the left reproductive tract
240,241,242
.  
AMH Expression in Adult Birds 
 AMH production continues in birds after hatching. In the prepubertal rooster, a ten-fold 
increase in AMH mRNA is observed in 12-week testes compared to E6 testes
243
. However, in 
sexually mature roosters, only negligible quantities of AMH mRNA were detected
243
. In avian 
and mammalian females, AMH is most strongly expressed in small follicles. In the adult hen, 
AMH continues to be produced by the ovary, with the highest levels of AMH mRNA detected in 
1 mm whole follicles
244
. AMH mRNA levels decrease as follicle size increases, with very low 
levels in the F1 (pre-ovulatory follicle) but moderate quantities in the ovarian stroma
244
.  
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AMH mRNA expression was negligible in the liver
244
. Immunohistochemistry studies detected 
AMH protein localization within granulosa cells of small follicles, and granulosa cells in close or 
distant proximity to the germinal disc did not reveal a gradient of AMH mRNA expression, as is 
sometimes observed in mammals
244
. AMH expression patterns in avian species correspond to 
similar temporal and spatial expression of AMH during mammalian sexual development and 
follicular development. 
 AMH mRNA expression in adult hens varies according to production type. AMH mRNA 
was evaluated in layer and broiler breeder hens, and was found to be greater across follicle sizes 
and within ovarian stroma in broiler hens
245
. In addition, metabolic status in adult hens also 
impacts AMH mRNA expression within developing follicles. The poultry industry utilizes a 
technique to improve egg production in broiler breeder hens. By reducing feed intake, ovulation 
becomes more consistent and follicular hierarchies are similar in appearance to those of layers. 
Broiler hens on reduced feed intake are termed Restricted-fed (RF), while hens on an ad libitum 
diet are referred to as Full-fed (FF). The physiological changes involving egg production and 
ovulation between RF and FF hens suggest modifications to the rate of the follicle development 
might be affected by metabolic status. AMH mRNA expression is increased in smaller follicles 
(3-5 mm) and within ovarian stroma of FF broiler breeder hens as compared to RF hens
245
. It is 
hypothesized that metabolic factors, including GH and IGF1, might contribute either directly or 
indirectly to these changes observed in AMH and follicular dynamics within the ovary. Indeed, 
GH-stimulated progesterone production within cultured granulosa cells, and GH mRNA and 
protein, as well as the GH receptor, are located in follicles
246,247
. 
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Regulation of AMH in Chickens 
 To date, regulation of AMH in avian physiology is largely uncharacterized. Cloning of 
the 1050-bp chick AMH promoter revealed moderately conserved regulatory binding sites, 
including two SOX, one SF1 and one estrogen-responsive site
236
. However, unlike mammalian 
physiology, gonadal AMH mRNA expression predates SOX9 mRNA expression, which does not 
appear until E6 in the avian testes. SOX9 mRNA increases substantially shortly before E7, and a 
parallel temporal increase is observed in AMH mRNA. Additionally, SOX9 and AMH mRNA 
colocalize within the testes. SOX9 mRNA was absent from the embryonic ovary
236
. Other 
members of the SOX family, including SOX8, -3, -4, and 11, were identified within the gonads 
at E6-7, but none exhibited a sex-bias
248
. 
 Other genes that contribute to sex determination were evaluated in chick embryonic 
gonads. DMRT1, a transcription factor, is present in both sexes, although a male-biased mRNA 
expression pattern develops between E5.5-7
235,249
. Knockdown of DMRT1 induces feminization 
of the testes, but over-expression of DMRT1 masculinizes the ovaries and downregulates 
aromatase
250
. Another transcription factor, SF1, displays a sexually dimorphic shift, as SF1 
mRNA is male-biased at E5.5, but reverses to exhibit a female-bias at E7.5-8.5
249
. SF1 has been 
shown to bind to the avian AMH promoter
251
. This modification in SF1 mRNA expression likely 
corresponds with increased AMH in the testes around E5.5.-6, as SF1 upregulates AMH 
expression in mammals. Furthermore, DAX1, a transcription factor that downregulates AMH 
expression by interfering with SF1 in mammals, becomes female-biased by E6.5-7.5, which may 
also contribute to the relatively static AMH expression in females
249
. Another transcription 
factor, GATA4, which is known to upregulate mammalian AMH, did not develop any changes in 
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mRNA expression between E5.5-8.5
249
. After hatching, AMH, SF1, GATA4 and WT1 mRNA 
are simultaneously expressed within the ovarian cortex
235
. 
 In the adult hen ovary, granulosa cells collected from 6-8 mm follicles were cultured with 
increasing dosages of estradiol or progesterone, but failed to induce changes in AMH mRNA 
expression
244
. Although the avian AMH promoter contains an estrogen responsive element, data 
from mammalian experiments reveal estradiol acting via ERα and ERβ increases and decreases 
AMH expression, respectively, in particular stages of follicular development. Granulosa cells 
from 3-5 and 6-8 mm follicles cultured with vitamin D displayed increased AMH and FSHR 
mRNA expression accompanied by increased cell proliferation, when compared to controls
252
. In 
addition, bidirectional communication between ooplasm and granulosa cells is known to exist in 
mammalian and avian follicles. To better identify the role of the oocyte in AMH regulation, 
granulosa cells sourced from 6-8 mm follicles were cultured with different dosages of Oocyte-
Conditioned Medium (OCM)
244
. AMH mRNA expression was inhibited on a dosage-dependent 
basis, supporting the hypothesis that the oocyte might help regulate AMH in the surrounding 
granulosa cells within the follicle. When the OCM was exposed to 65°C for 30 minutes, the 
inhibiting effect provided by the OCM disappeared, indicating a heat-dependent factor within the 
oocyte was likely regulating AMH
244
. In an effort to better understand the downstream effects of 
AMH in the adult ovary, granulosa cells from 3-5 and 6-8 mm follicles were cultured in the 
presence of different dosages of Testis-Conditioned Medium (TCM) and/or AMH antibody
245
. 
Proliferation rates increased with TCM dosage, but declined when an AMH antibody was 
included
245
. 
 Members of the BMP family also contribute to AMH regulation in the chicken, similar to 
their effects in mammalian signaling pathways. In addition to BMP genes, members of the ID 
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family and AMH are hypothesized to contribute to an FSH-responsive regulation of follicular 
differentiation and further development. BMP6 (rhBMP6), primarily located within granulosa 
cells of smaller follicles (1-5 mm), has been shown to increase both AMH and FSHR mRNA in 
cultured granulosa cells collected from 6-8 mm follicles
253
. Granulosa cells cultured with BMP4 
and FSH also increase AMH and FSHR mRNA levels, in addition to cAMP
254
. BMP2 
significantly increases ID3 and decreases FSHR mRNA expression in cultured granulosa cells
255
. 
ID3, as well as ID1 and -4, have been shown to decrease FSHR mRNA within granulosa cells
256
. 
This data suggests FSH is regulated via a paracrine and autocrine manner through systematically 
modified expression of its receptor, FSHR, which is a membrane-bound receptor located on 
granulosa cells
257,258
.  
 Within avian physiology, the downstream effects of AMH beyond müllerian duct 
regression are not well known. Suppression of AMH in vitro and in vivo via RNA interference 
utilizing short hairpin RNA (shRNA) resulted in stunted gonadal growth, which was observed in 
both sexes from E4.5-7.5, due to suppressed cellular growth and decreased germ cell populations 
within testes
259
. Similarly, AMH overexpression using viral vectors led to underdeveloped, 
moderately masculinized gonads that lacked steroidogenic capabilities in either embryonic sex, 
as well as proper spermatogenesis functions in males
260
. The effects of AMH overexpression 
were continued in vivo in adult chickens of both sexes (nine of the 812 microinjected eggs 
hatched; 1.11%): four females and two males. At the time of sexual maturity (<18 wks post-
hatching), the birds overexpressing AMH failed to display any sexually dimorphic traits except 
weight, though they had a small, pale comb and some females exhibited a spur characteristic of 
males
260
. Serum estradiol levels in control females ranged from 531-2205 pmol/L, compared to 
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undetectable levels in three of the four treatment hens
260
. Testosterone levels were also lower in 
the two treatment males versus controls.  
AMHRII in the Chicken 
 While AMH provides critical functions within avian species, little is known about avian 
AMHRII. Identified in RNA-Seq reads as early as E4.5, AMHRII is estimated to be 
approximately 547 amino acids long, although the full nucleotide sequence has not yet been 
available publicly or published
261
. On E4.5-8.5, the müllerian ducts and gonads of both sexes 
showed AMHRII protein localization via IHC. When treated with an aromatase inhibitor, 
AMHRII protein increased within the ovarian medulla, which underwent a degree of 
masculinization
261
. When DMRT1 was knocked down, AMHRII protein expression decreased in 
male embryos to a feminized expression level. 
V. The Modern Hen as a Model to Study the AMH/AMHRII Signaling Pathway 
 Two main hen types exist in modern commercial poultry production systems: the layer 
hen--a lighter, physically refined hen selected for efficient and prolific egg production, and the 
broiler hen--a much larger hen selected for robust growth patterns and relatively extreme muscle 
development to meet the consumer demand for poultry. The layer hen regularly maintains a full 
follicular hierarchy, ovulating almost daily with only minor interruptions. Unlike layers, broiler 
hens selected to produce offspring typically have irregular egg production, which is problematic 
for broiler producers who desire to replenish their poultry stocks. The full-fed broiler breeder hen 
produces an over-developed follicular hierarchy, which causes irregular ovulation patterns, 
resulting in double or missed ovulations
245
. When broiler breeder hens are placed on a restricted 
diet, however, ovarian function is less excessive and more closely resembles that of a layer 
hen.AMH, which helps regulate follicle recruitment and development in mammals, has been 
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hypothesized to contribute to the differences observed between broiler breeder and layer 
ovaries
245
. 
 During molting, which can be stimulated or spontaneous, the hen enters a 
hypogonadotropic state and the ovary regresses, with no follicles entering the follicular 
hierarchy
262,263
. This is often characterized by feather loss and replacement. Commercial 
chickens are typically maintained on long days for prolonged periods and they ovulate and lay 
eggs throughout the year. In contrast, wild birds are highly responsive to prevailing photoperiod, 
limiting follicle development to a very restricted portion of the year. Although the period of molt 
of anovulation in commercial chickens is of shorter duration than that which occurs in wild 
species, in both cases, the regressed ovary is accompanied by a hypogonadotropic state. We have 
hypothesized that these anovulatory periods may mandate protection of the ovarian reserve as 
observed in short day-reared, hypogonadotropic Siberian hamsters
214
. Evaluation of AMH within 
the ovary during these different reproductive statuses, including in and out of molt, may provide 
evidence for AMH involvement in protecting the ovarian reserve, as well as during 
folliculogenesis and follicle activation.  
VI. Conclusion 
 While extensive research has already been performed, many aspects of AMH and 
AMHRII have yet to be clarified in both mammalian and avian physiology. The role of  
AMH as a critical reproductive hormone has been discovered to include processes outside of 
embryonic development and testicular processes and regulation. AMH action in the ovary, 
including early and developing follicular dynamics, still needs to be explored. Investigation of 
AMH apart from strict gonadal functions, such as its contributions in brain and neuronal 
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processes, is a quickly developing field of interest. In addition, the autocrine and paracrine 
regulation of AMH and AMHRII remains unclear. 
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CHAPTER II 
AMHRII IN AVIAN FOLLICLE DEVELOPMENT 
I. Abstract 
 In the mammalian ovary, anti-müllerian hormone (AMH) helps maintain the ovarian 
reserve by regulating primordial follicle activation and follicular selection, although its role 
within the avian ovary is unknown. In adult mammals, AMH is primarily produced in granulosa 
cells of preantral and early antral follicles. Similarly, in the hen, the granulosa cells of smaller 
follicles are the predominant source of AMH. AMH importance in mammalian ovarian dynamics 
suggests AMH may have conserved, protective functions within developing follicles in the hen. 
To better understand the role of AMH in avian follicle development, we studied the expression 
pattern of the specific AMH receptor. AMH utilizes the TGF-β/SMAD signaling pathway, 
including the specific Type II receptor, AMHRII. qRT-PCR results indicate that AMHRII 
mRNA expression, as well as that of AMH, are highest (p<0.01) in small follicles (1 mm) and 
decrease as follicle size increases. Dissection of 3-5 mm follicles into ooplasm and granulosa 
components shows that AMHRII mRNA levels are significantly greater in ooplasm than 
granulosa cells. Immunohistochemistry revealed AMHRII staining in the oocyte and granulosa 
cells. In mammals, AMH expression is elevated during periods of reproductive dormancy, 
possibly protecting the ovarian reserve. To assess the expression of AMHRII and AMH during a 
similar state in chickens, we evaluated mRNA expression in a broiler strain and an egg-laying 
strain of hens in different reproductive states. AMH and AMHRII mRNA were significantly 
higher (p<0.05) in non-laying ovaries of broiler hens. In molting (with documented feather loss) 
and non-molting layer hens, AMHRII mRNA was significantly greater (p<0.05) in molting hen 
ovaries. These results suggest AMH may contribute to the intra-follicular bidirectional 
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communication between oocyte and granulosa cells, and support a potential role of AMH in 
limiting follicle recruitment in hens. 
II. Introduction 
Much of the success behind the modern commercial laying hen lies in its highly 
coordinated reproductive proficiency, making it a valuable animal model for studying successful 
ovarian function. The hallmark of an efficient laying hen is the maintenance of a precise 
follicular hierarchy, where follicles continuously develop and ovulate according to size, ideally 
resulting in one daily egg. Current research in the hen attempts to elucidate the delicate hormonal 
regulation and intercellular communication that masterfully controls this follicular hierarchy. In 
the mammalian ovary, anti-müllerian hormone (AMH) is critical in helping maintain the ovarian 
reserve by regulating primordial follicle activation and follicular growth and selection 
(Durlinger, et al. 2001; Durlinger, et al. 2002). AMH importance in mammalian ovarian 
dynamics suggests AMH may have conserved, protective functions on the ovarian reserve and 
within developing, perihierarchal follicles in the hen. 
 In many mammalian species, a primary function of AMH in the ovary is to regulate 
primordial follicle activation from the ovarian reserve (Durlinger, et al. 2002; Rocha, et al. 
2016). A secondary role of AMH is to help regulate the development of gonadotropin-dependent 
follicles. AMH has been shown to reduce FSH sensitivity in follicles (Durlinger, et al. 2001; 
Campbell, et al. 2012). Two micro-RNAs, miR-181a and miR-181b, have recently been 
identified as targets of AMH. AMH is believed to upregulate these micro-RNAs, reducing intra-
follicular cAMP levels and thus FSH sensitivity (Hayes, et al. 2016). A third proposed function 
of AMH in the ovary relates to periods of reproductive quiescence. During these times, AMH 
mRNA expression increases, suggesting that AMH limits follicular recruitment and development 
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during times of restricted fertility (Nilsson, et al. 2007; Kabithe and Place, 2008; Shahed, et al. 
2013). To date, the mechanism of action underlying this phenomenon has yet to be identified. 
Ovarian factors including BMP15 are involved in the regulation of AMH. BMP15 upregulates 
AMHRII mRNA expression in human and ovine granulosa cells (Pierre, et al. 2016).  
 In mammals, AMH utilizes two TGF-β type receptors (Grootegoed, et al. 1994; Josso, et 
al. 2001). AMH first binds to the extracellular portion of its specific (Mishina, et al. 2009) 
primary receptor, AMH Type II Receptor (AMHRII), which subsequently phosphorylates one of 
three non-specific Type I receptors: ALK2/ACVR (Visser, et al. 2001; Clarke, et al. 2001), 
ALK3/BMPR1A (Wu, et al. 2012; Sèdes, et al. 2013) or ALK6/BMPR1B (Zhan, et al. 2006). 
Once AMH binds both receptors, the AMH-receptor complex triggers the SMAD signaling 
cascade, phosphorylating three receptor-regulated Smads (R-Smads) within the cellular 
cytoplasm: Smad1, Smad5 and Smad8 (Hutson, et al. 1984; Dutertre, et al. 2001; Zhan, et al. 
2006; Orvis, et al. 2008; Kristensen, et al. 2014). The three activated R-Smads then complex 
with common-mediator Smad4, stimulating active transcription factor formation within the 
nucleus (Gouédard, et al. 2000). 
 In mammalian females, AMH is most strongly expressed in small follicles (Baarends, et 
al. 1995). In the adult hen, AMH is produced in granulosa cells of follicles, with the highest 
levels of AMH mRNA detected in 1 mm whole follicles (Johnson, et al. 2008). AMH mRNA 
levels decrease as follicle size increases, with very low levels in the pre-ovulatory (F1) follicle 
(Johnson, et al. 2008). Immunohistochemistry studies detected AMH protein localization within 
granulosa cells of small follicles, and there was no gradient of AMH mRNA expression in 
granulosa cells relative to the germinal disc (Johnson, et al. 2008), as is sometimes observed in 
mammals (Kedem, et al. 2014). 
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 Two main types of chickens have been selected in modern commercial poultry 
production systems: the layer hen, which is a lighter hen selected for efficient and prolific egg 
production, and the broiler hen, which has been largely selected for robust growth and muscle 
development for meat. A similar pattern of AMH mRNA expression was found in developing 
follicles of laying and broiler hens, although the absolute quantity of AMH mRNA was greater in 
broiler hen ovaries (Johnson, et al. 2009).  
 While avian AMH is biologically active in mammals, mammalian AMH fails to activate 
müllerian duct regression in avian species (Josso, et al. 1977), possibly resulting from low 
homology in the binding region of AMH or extracellular region of AMHRII. It is possible that 
information about AMHRII expression and regulation may help clarify AMH function in birds. 
Identified in the chicken in RNA-Seq reads as early as E4.5, AMHRII is estimated to be 
approximately 547 amino acids long, although the full nucleotide sequence is not yet available 
(Cutting, et al. 2014). The first objective of this research was to characterize AMHRII mRNA 
and protein expression in the adult hen ovary to better understand the potential roles of AMH in 
avian reproductive physiology. The second objective was to evaluate AMH and AMHRII in 
different reproductive states. Finally, we evaluated regulation of AMH by the oocyte factor 
BMP15. We hypothesized hen granulosa cells treated with BMP15 would exhibit an increase in 
AMHRII mRNA expression. 
III. Materials and Methods 
Animals and Treatment Protocols 
 Commercial strains of Single-comb White Leghorn laying hens (Babcock B300 and 
Shaver) were used. The hens were individually caged, with egg records maintained daily. All 
hens had ad libitum food and water, and were maintained on 15 h light: 9 h dark (lights on at 
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0600 h). Hens between 8-21 mo of age and laying regularly were euthanized via CO2 1.5-2.5 h 
post oviposition. Embryos (embryonic day 6-12; E6-12) used in immunofluorescence or protein 
lysates were a Cornell laying strain. 
 Fifteen-month old broiler breeder hens on a restricted diet were also used and were 
housed in floor pens. Non-laying broiler breeder hens (n=5) exhibited small, pale combs, yellow 
shanks, and fully regressed ovaries. Broiler hens which were laying (n=7) had large, red combs, 
full follicular hierarchies, and were trapped in a nesting box after laying an egg. Laying hens 
were induced to molt with dietary supplementation of ZnO2 (Goodman, et al. 1986) or molted 
spontaneously. In all molting cases, feather loss was documented and the ovary was regressed. 
Non-molting hens of the same age were used as controls to the molting hens. All animal care and 
procedures were approved by the Institutional Animal Care and Use Committee of Cornell 
University. 
Sequencing 
 The validated Mus musculus and predicted Falco peregrinus AMHRII sequences were 
aligned and primers were designed using Primer3 and OligoAnalyzer from the aligned F. 
peregrinus sequence. Based on earlier work on AMH in the hen, cDNA from 1 mm whole 
follicles from an adult layer hen was chosen as the template for PCR. The resulting PCR product 
was sequenced and analyzed (see Appendix). Additionally, the PCR product matched 
unpublished cDNA from Cutting and colleagues (2014). 
 In a second effort to sequence AMHRII, the predicted chicken AMHRII coding sequence 
available on NCBI (from Gallus gallus 5, uncharacterized LOC101749915, Chr. 33, 829,346-
832,058 bp) was used to design overlapping PCR primer pairs spanning the 5' untranslated 
region (UTR), predicted 1101 bp coding sequence, and 3' UTR. For template, cDNA from 1 and 
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3 mm whole follicles from an adult layer ovary were used. An additional reagent, preCESII, was 
made with H2O in lieu of BSA and used as directed in several PCR reactions (Ralser, et al. 
2006). An aliquot of all the PCR products was run with loading dye on a 1.5% agarose gel 
containing Ethidium Bromide at 106 V for approximately 46-55 min and imaged. If a single 
band or multiple bands were present, the PCR product or excised band of interest, respectively, 
was purified according to manufacturer's instructions (Qiagen, Valencia, CA, USA; QIAquick 
Gel Extraction Kit; Cat. No. 28704). The purified PCR product was then combined with the 
forward or reverse primer (10 pmol/µL) and diluted to approximately 10 ng total nucleic acid 
immediately prior to submission for sequencing at the Biotechnology Resource Center at Cornell 
University. PCR products were sequenced in both directions to increase sequence accuracy (see 
Appendix). 
Tissue Collection and RNA Isolation 
 Fresh tissues were immediately placed into cold Krebs-Ringer bicarbonate buffer on ice 
prior to dissection or subsequent storage. Whole follicles (1, 3, 5 mm) and liver samples were 
used fresh or immediately flash frozen or frozen in RNAlater Stabilization Solution (Thermo 
Fisher Scientific, Cat. No. AM7021) at -80°C, and homogenized immediately preceding RNA 
isolation. Granulosa cells and ooplasm were collected from individual 3-5 mm follicles of a hen 
and pooled (n=8-10 hens), as previously described in Stephens and Johnson (2016) and Wang et 
al. (2007). Granulosa cells were also collected from 3-5, 6-8, 9-12 mm and F1 follicles (n=5-6 
hens) for mRNA expression. For granulosa cell culture, granulosa cells were isolated from 3-5 
and 6-8 mm (n=5-6). Cells were dispersed and cultured as previously described (Stephens and 
Johnson, 2016). Recombinant human BMP15 (rhBMP15) (R&D Systems, Minneapolis, MN) 
was added to the cultures at doses of 0, 10, and 25 ng/mL. 
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 RNA from follicles (1, 3, 5 mm), liver tissue (n=4-5), ooplasm, granulosa cell layers and 
cultured granulosa cells was extracted using the RNeasy Mini Kit (Qiagen, Cat. No. 74106) 
according to manufacturer's instructions, including on-column DNA-digestion with RNase-free 
DNase (Qiagen, Cat. No. 79254). RNA from total ovarian tissue (cortex tissue without ≥1 mm 
follicles) from laying hens (n=16, 16) and from broiler breeder hens (n=7,5) was extracted using 
the RNeasy Fibrous Tissue Mini Kit (Qiagen, Cat. No. 74704) according to manufacturer's 
instructions. 
Reverse Transcription and qRT-PCR 
 RNA was analyzed for quality and concentration using an Implen NanoPhotometer 
UV/Vis spectrophotometer before cDNA synthesis was performed according to manufacturer's 
instructions (Applied Biosystems, High-Capacity cDNA Reverse Transcription Kit, Cat. No. 
4368814) and with RNase Inhibitor (Applied Biosystems, Foster City, CA, USA; Cat. No. 
N8080119). For AMHRII, custom Invitrogen primers were designed from our initial AMHRII 
sequence information using Primer3 software. For qRT-PCR, 25 µL reactions were run in 
duplicate using AB StepOnePlus Real-Time PCR System (Thermo Fisher Scientific, Waltham, 
MA, USA; Cat. No. 4376600) containing 1X Power SYBR Green (Applied Biosystems, Cat. No. 
4368706) and 300 nM of primer pairs (Table 2.1). All sample reactions were normalized to 
duplicate 18S rRNA reactions (Applied Biosystems, QuantumRNA 18S Internal Standards Kit, 
Cat. No. AM1718) as an endogenous control. Control reactions lacking template or reverse 
transcriptase were run concomitantly. Mean expression levels of all normalized samples were 
analyzed using a 9-point standard curve containing serial dilutions of pooled cDNA from 1, 3, 
and 5 mm whole follicles from an adult laying hen. 
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Western Blot 
 Protein lysates were made from pooled E11-12 testes, granulosa cells from 3-5 mm and 
F1 follicles (n=4 hens), 1, 2, <2, 3, 4, 5, 6 mm whole follicles, and liver. A non-interfering 
Tissue Lysis Buffer (1 M HEPES, pH 7.5; 5 M NaCl; 20% Triton X-100; 0.5 M EDTA; 100 mM 
Na. PyroPhos.; 100 mM Na. OrthoVand.; 100 mM PMSF; 1 M NaF; Protease Inhibitor Cocktail 
(Sigma Aldrich, St. Louis, MO, USA; Cat. No. P8340)) and distilled H2O were used. To 
determine protein concentrations, protein lysate samples were run in duplicate using a Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific, Cat. No. 23225) according to manufacturer's 
instructions. Fifty or 75 µg of total, freshly thawed protein (equal total protein loaded per gel) 
were subjected to SDS-PAGE with β-Mercaptoethanol and run on a 12% polyacrylamide gel 
(Thermo Fisher Scientific, Precise™ 12% Tris-HEPES Gels, Cat. No. 25202) for approximately 
40-54 minutes at 106 V, then transferred onto a nitrocellulose membrane for 77-80 minutes at 
400 mA at 4°C. The membrane was then blocked in 5% BSA in 1X phosphate-buffered saline 
with 0.1% Tween-20 (PBST) for 1 hr, evaluated with Ponceau S Stain to confirm protein transfer 
from the gel to the membrane, and incubated overnight at 4°C with 1:2000 AMHRII (custom 
polyclonal rabbit anti-chicken AMHRII antibody generously donated by Dr. Craig Smith 
(Cutting, et al. 2014, Lambeth, et al 2016), in 1% non-fat dried milk (NFDM) in PBST in a 
sealed bag. Primary antibody was retained, stored at 4°C and reused in subsequent 
immunoblotting runs. After incubation with the primary antibody, the membrane was washed in 
PBST three times for 10 min each and incubated with goat anti-rabbit HRP-conjugated 
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; Cat. No. SC-2030) at 
1:5000 in 5% NFDM in PBST for 1 hr at room temperature, followed by three PBST washes for 
10 min each. Immediately before imaging, membranes were incubated with Clarity Western ECL 
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Substrate (Bio-Rad, Hercules, CA, USA; Cat. No. 1705060) for 5 min at room temperature. 
Bands were visualized and recorded using a Fluor Chem HD2 Imager (Alpha Innotech, Protein 
Simple, San Jose, CA, USA). As an endogenous control, membranes were incubated with 1:3000 
β-actin mouse anti-mouse primary antibody and 1:5000 goat anti-mouse HRP-conjugated 
secondary antibody (Thermo Fisher, Cat. No. 31430) and imaged as described above. 
Immunofluorescence 
 The same custom polyclonal rabbit anti-chicken AMHRII antibody was used to localize 
AMHRII binding in control and sample tissues. Embryonic testes (E11-12) were used as a 
positive control and to demonstrate the successful replication of the fixation and 
immunofluorescence procedures described in Cutting, et al. 2014. Fresh tissue, including pooled 
E11-12 testes and 1, 3, and 5 mm whole follicles (n=3 hens), from adult laying hens were fixed 
for cryosections according to the procedures detailed in Cutting, et al. (2014). Cryosection blocks 
were sectioned at 5 µm at the Histology Laboratory at the Cornell University Veterinary School, 
and sections (hematoxylin and eosin) were examined prior to use. The immunofluorescence 
protocol previously described (Cutting, et al 2014) was modified for cross sections of ovarian 
and follicular tissues: AMHRII antibody was increased to 1:750; 10% goat serum IgG in 5% 
NFDM in PBS was used to block; and a 10 min thaw at room temperature was included before a 
3 hr soak in PBS at room temperature. The secondary antibody was 1:750 goat anti-rabbit Alexa 
Fluor 555 (Thermo Fisher Scientific, Cat. No. A-21429), and slides were incubated with Hoechst 
33358 (1:1000 in H2O) for 15 min at room temperature for nuclear staining. Tissues were imaged 
using a Nikon Eclipse E600 microscope with light and fluorescent capabilities and a Spot RT 
Slider camera. 
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Statistical Analyses 
 Messenger RNA expression from qRT-PCR data was analyzed using a one-way 
ANOVA. When significance was detected, means were compared using Tukey's test, and P 
values of <0.05 were considered significant. All statistical analyses were performed using 
GraphPad Prism (Version 6.0 for Windows, GraphPad Software, La Jolla, CA, USA,  
www.graphpad.com). 
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Table 2.1. Primers used for qRT-PCR. 
  
Gene Accession No. Prod. Size (bp) Primer (5'-3') 
AMH U61754 71 F - CCCCTCTGTCCCTCATGGA 
   R - CGTCATCCTGGTGAAACACTTC 
AMHRII N/A 180 F - GCAGGTTCCAGACTCTCATCC 
   R - CAGCAGTCAGAACGTGTTGG 
BMP15 AY725199 197 F - ACATGCTGGAGCTGTACCAA 
   R - GACACGGAGAAGGTGCTCA 
GDF9 AY672110 89 F - ACTTTTCACCCCGTGTTCTG 
   R - CCAGGTTGAAGAGCAAATCC 
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IV. Results 
 A 247-bp sequence of AMHRII was found to be 81% identical to the predicted F. 
peregrinus sequence. Strong conservation in this region of AMHRII suggests the sequence spans 
the intron between Exons 8 and 9. This sequence was also present within a partial AMHRII 
cDNA sequence (Cutting et al, unpublished) and later gene annotations in NCBI. A 180-bp sub-
sequence was utilized as a probe for qRT-PCR to evaluate mRNA expression. Additional 
sequence of AMHRII was obtained for a total sequence length of 532 bp. All primer sequences 
and resulting trace images and raw sequences from successful sequencing reactions are available 
in the Appendix. 
 To determine the potential involvement of AMHRII in folliculogenesis, AMHRII mRNA 
expression levels were evaluated across different follicle sizes, and found to decrease 
significantly as follicle size increases (p<0.01) (Figure 2.1). AMHRII was significantly (p< 0.05) 
greater in 1 mm follicles compared to 5 mm follicles; AMHRII mRNA was undetectable in liver. 
Within granulosa cells from small (3-5 mm), developing (6-8, 9-12 mm), and the pre-ovulatory 
(F1) follicles, both AMHRII (p<0.001) and AMH (p<0.01) mRNA expression were significantly 
highest in 3-5 mm follicles (Figure 2.2). Messenger RNA expression was examined in ooplasm 
and granulosa cells collected from 3-5 mm follicles (Figure 2.3). AMHRII mRNA was also 
significantly higher in ooplasm than in granulosa cells (p<0.04). However, similar levels of 
AMH mRNA expression were found in both ooplasm and granulosa (p=0.7591), likely 
indicating some granulosa cell contamination of the ooplasm. To evaluate separation of the two 
follicular components, two known oocyte-specific factors, BMP15 (p<0.01) and GDF9 (p<0.05), 
were assessed in these follicular compartments and found to be significantly higher in ooplasm 
and negligible in granulosa cells, as expected. 
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Figure 2.1  AMHRII mRNA expression across different whole follicle sizes and tissues. 
 
 
 
 
 
 
AMHRII 
 
** 
*  p<0.05 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2   mRNA expression from granulosa cells from different follicle sizes. 
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Figure 2.3   mRNA expression in ooplasm and granulosa of 3-5 mm follicles. 
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 In laying and non-laying broiler breeder hens, both AMHRII (p<0.05) and AMH 
(p<0.05) mRNA expression were higher in non-laying hens (Figure 2.4). AMHRII mRNA 
expression was significantly higher in molting hens as compared to non-molting hens (p<0.03), 
while AMH mRNA levels were not different (p=0.56) (Figure 2.5). rhBMP15 at 25 ng/mL 
significantly decreased (p<0.05) AMHRII mRNA in 3-5 and 6-8 mm granulosa cells and also 
decreased AMH mRNA in 6-8 mm granulosa cells (Figure 2.6). 
 AMHRII western blots yielded a main band between 60-80 kDa in whole follicles 
(Figure 2.7). As follicle size increases, an additional band between 30-40 kDa strengthens. β-
actin, at approximately 42 kDa, was evaluated as an endogenous control. AMHRII protein 
expression in Western blot using protein from 3-5 mm and F1 granulosa appears at a similar size, 
although much less intense than that in whole follicles (data not shown). 
The results of AMHRII immunofluorescence within Sertoli cells in the E12 testis 
successfully replicated the results found in Cutting, et al. (2014) (Figure 2.8). 
Immunohistochemistry showed AMHRII protein localization within the oocyte and granulosa 
cells of small intra-ovarian follicles (Figure 2.9). Binding in the oocyte displayed a centralized 
binding pattern. When the primary antibody was replaced with 10% goat serum, the signal was 
absent in both the testis and follicle. 
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Figure 2.4  mRNA expression in total ovarian tissue from laying and non-laying restricted-fed 
broiler breeder hens. 
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Figure 2.5  mRNA expression in total ovarian tissue from molting and non-molting layer hens. 
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Figure 2.6  AMH and AMHRII mRNA expression in granulosa cells from 3-5 and 6-8 mm 
follicles treated with different doses of rhBMP15. 
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Figure 2.7  Western Blots of AMHRII in various avian tissues: A: 2 mm Whole Follicle (WF); 
B: 4 mm WF; C: 6 mm WF. β-actin as endogenous control shown below respective lanes.  
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Figure 2.8  Immunofluorescence of rabbit anti-chicken AMHRII antibody in cross sections of 
E12 rooster testes. Hoechst (blue) as nuclear stain (A,C); 10% goat serum substituted for 
antibody (B); rabbit anti-chicken AMHRII antibody (D); goat anti-rabbit Alexa Fluor 555 (Red) 
(B, D); merged images (E,F); H&E (G). Size bar equals 100 µm.  
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Figure 2.9  Immunofluorescence of rabbit anti-chicken AMHRII antibody in adjacent cross 
sections of intraovarian follicles (Follicles A and B) within the cortex of adult layer hens. 
Hoechst (blue) as nuclear stain; 10% goat serum substituted for antibody; goat anti-rabbit Alexa 
Fluor 555 (Red). Size bar equals 100 µm. 
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V. Discussion 
  To our knowledge, this is the first time AMHRII has been characterized in the adult hen 
and throughout ovarian follicle development. Sequencing of AMHRII in the chicken remains 
incomplete, although we sequenced 532 bp, likely representing a large portion of the C-terminus 
(bp 928-1460 of an estimated 1735 (encompassing coding sequence and both UTR)). AMHRII 
mRNA expression was highest in 1 mm whole follicles and decreased as follicle size increased. 
This notable decline in both AMH and AMHRII mRNA expression strongly correlates with 
increasing follicle size, suggesting AMH plays a primary role in early follicle development, prior 
to yolk accumulation and recruitment into the follicular hierarchy. AMHRII mRNA was also 
highest in granulosa cells from 3-5 mm follicles, and was almost negligible in F1 granulosa.  
 Interestingly, AMHRII mRNA expression was significantly higher in ooplasm as 
compared to granulosa cells. AMHRII has been historically reported to directly colocalize with 
AMH in granulosa cells within follicles (di Clemente, et al. 1994). However, our results 
indicated significantly higher levels of AMHRII mRNA in ooplasm than in granulosa cells. 
Additionally, immunofluorescence results show strong localization of AMHRII protein within 
the oocyte, though this could be an artifact. These findings are supported by the results of in situ 
hybridization studies of small antral follicles in the rat (Baarends, et al. 1995). Baarends' studies 
show AMHRII mRNA signal throughout the oocyte and granulosa of some follicles. Subsequent 
studies have primarily investigated AMHRII mRNA and protein expression within granulosa 
cells, although AMH was localized in oocytes and granulosa cells within caprine (Rocha, et al. 
2016) and Atlantic salmon (von Schalburg, et al. 2013) follicles via IHC. 
 Surprisingly, AMH mRNA levels were comparable in the ooplasm and granulosa, likely 
indicating granulosa contamination in the ooplasm samples. This is interesting because our 
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previous IHC data showed intense staining for AMH in the granulosa layer (Johnson, et al. 
2008), and AMH has repeatedly been found only within granulosa cells of a variety of species 
(Takahashi, et al. 1986; Bézard, et al. 1987; Münsterberg and Lovell-Badge, 1991; Modi, et al. 
2006). Oocyte-specific BMP15 and GDF9 mRNA levels show that there is extremely low 
contamination of ooplasm in granulosa cells. This is likely due washing the granulosa cells prior 
to RNA extraction. In contrast, it was not feasible to “wash” the aqueous ooplasm before 
extraction. Future refinement of ooplasm collection techniques, including filtering and 
centrifugation, could increase the purity of ooplasm samples.  
 AMHRII western blots results show a strong protein band between 60-80 kDa. The full 
chicken AMHRII peptide sequence and molecular weight are unknown, although Cutting et al. 
(2014) estimated the chicken AMHRII sequence to be 514 AA. Human AMHRII is 573 AA, and 
is observed at approximately 83 kDa on a Western blot, while the European seabass and Fugu 
pufferfish are only 499 and 514 AA, respectively. A shorter amino acid sequence in the chicken 
might yield a smaller band than what is observed in mammals. In the mouse, different AMHRII 
forms have been identified at approximately 58 and 66-68 kDa, depending on glycosylation and 
disulfide bond cleavage (Hirschhorn, et al. 2015). Finally, a second band at approximately 40 
kDa is visible in whole follicles 4 mm and greater; this band from an unidentified protein seems 
to intensify as follicle size increases. To date, AMHRII has not been reported to yield a protein 
form similar in weight to the 40 kDa band. AMHRII protein expression in Western blots from 3-
5 mm and F1 granulosa appear at a similar size, although much less intense than that in whole 
follicles, supporting the hypothesis that the AMHRII in the oocyte may be very important in 
bidirectional communication between the oocyte and the granulosa cells. 
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 BMP15 is an oocyte-specific protein that has been shown to regulate AMHRII. When 
granulosa cells were treated with rhBMP15, AMHRII and AMH mRNA expression decreased 
significantly, contrary to the effects of BMP15 on AMHRII in humans (Pierre, et al. 2016). 
BMP15 increased AMHRII mRNA expression within luteinized human and ovine granulosa 
cells, as well as increased AMHRII promoter activity within ovine granulosa cells (Pierre, et al. 
2016). Perhaps a species or dosage difference, or cellular location of AMHRII, is responsible for 
the difference between these two studies. Our earlier work using oocyte conditioned medium 
(OCM) revealed an oocyte factor was capable of decreasing AMH mRNA expression (Johnson, 
et al. 2008). BMP15 may possibly decrease both AMH and AMHRII in the granulosa cells and 
oocyte. During follicular development, both AMH and AMHRII mRNA levels decrease at the 
time of follicle selection and growth. Signals from the oocyte, such as BMP15, might act through 
an autocrine mechanism or interact with the surrounding granulosa cells to permit the acquisition 
of FSHR and thus allow the follicle to develop. 
 Reproductive state also seemed to play a role in AMH and AMHRII expression. AMHRII 
mRNA expression was up-regulated in both the molting layer hens and the non-laying broiler 
breeder hens. AMH mRNA was significantly higher in non-laying broiler breeder hens. In 
mammals, reproductive dormancy correlates with increased AMH protein levels in the ovary 
(Kabithe and Place, 2008). In the hen, both AMH and AMHRII seemed to be influenced by the 
reproductive state. If AMH is important in regulating the rate of follicle recruitment, these date 
support our hypothesis that AMH and AMHRII help protect the hen's ovarian reserve, possibly 
by inhibiting folliculogenesis. 
 Further work to evaluate the direct effects of AMH in the hen is warranted. Factors that 
affect the AMH/AMHRII signaling pathway in mammalian physiology, including members of 
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the GATA (Beau, et al. 2000) and SOX (De Santa Barbara, et al. 1998; Arango, et al. 1999; 
Schepers, et al. 2003) families, may perform comparable roles in the chicken. Likewise, 
downstream targets in mammals include ID3 and the newly identified microRNA-181a and 
microRNA-181b (Hayes, et al. 2016). Transcription factors and downstream targets of 
AMH/AMHRII in the chicken should be identified. In addition, manipulating the regulatory 
elements supporting the AMH/AMHRII signaling pathway might influence oviposition rates by 
modifiying the rate of folliculogenesis. 
VI. Conclusion 
 In conclusion, AMHRII was characterized in folliculogenesis and ovarian dynamics to 
better understand the potential reproductive role of AMH in the hen. AMH and AMHRII mRNA 
and protein are present in small whole follicles. AMH could be exerting an effect on the oocyte, 
as AMHRII mRNA has been found at higher levels in ooplasm than in granulosa cells. High 
AMH/AMHRII mRNA expression early in folliculogenesis may indicate AMH plays a role in 
regulation of follicular activation and development. The increase in AMHRII mRNA during 
periods of suppressed follicular growth points to a potential inhibitory effect of AMH on the 
follicular pool. Future work should identify direct transcription factors involved in the 
AMH/AMHRII signaling pathway in chickens, and continue to investigate the mechanisms of 
action utilized by AMH/AMHRII regarding bidirectional communication between the ooplasm 
and granulosa cells. 
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APPENDIX 
 
Primers used for sequencing AMHRII. References for Primer Set Regions: 1: 5' UTR/N 
Terminus, 2: Middle Region, 3: C Terminus/3' UTR. Letters within Primer Set name represent a 
different primer set targeting the same region. 
 
Primer Set Prod. Size Primer (5'-3') Outcome 
F. peregrinus 
aligned with 
M. musculus 
272 bp F - GATCTCCCAGAGGAGCAGTG 
 
Sequenced - 928-1170 bp 
AMHRII 
  R - TGTACAAGCCCAGTGTGGTG Not Sequenced 
PS1 581 F - CCAACACGTTCTGACTGCTG Sequenced - Primer Overlap 
  R - CATGGGTGCATGGCGATG Sequenced - Primer Overlap 
PS1a 448 F - AAGGAAGTGCTGCAGGGAG No Band 
  R - GGTGGTGCTTGGACCCAT No Band 
PS1b 463 F - CTGGCGAAGGAAGTGCTG  No Band 
  R - TAACGGGGTGGTGGTGCTT  No Band 
PS2 501 F - GCAGGTCCAGACTCTCATCC Sequenced - 1002-1460 bp 
AMHRII 
  R - GCCCGGTCGCCATAAAAG Sequenced - 961-1423 bp 
AMHRII 
PS3 565 F - AGAAACTGCTCCGGAACCTC Sequenced - Failed 
  R - CAGCAGTCAGAACGTGTTGG Band; Not Sequenced 
PS3a 583 F - GGTCCCACATGGCAGAAACT No Band 
  R - GACCTCAGCAGTCAGAACGT No Band 
PS3b 576 F - GGGTCCCACATGGCAGAA Sequenced - 
Transmembrane protein 59 
  R - CAGTCAGAACGTGTTGGTGC Sequenced - 
Transmembrane protein 59 
PS3c 538 F - CTTCTTTGCCGCCTTCTTGT No Band 
  R - CACGCAGCGCTATTTGGC No Band 
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All trace images and raw sequences from successful sequencing reactions. 
 
F. peregrinus aligned with M. musculus: 
 
NCATGGCCTCACAGCGNGCGGCCCACCACCAGCGCAGGTTCCAGACTCTCATCCAG
GATCTCGGGGGCCAAATAGCGCTGCGTGCCCGCCCTGCGGATGTCCCCTCTCTGCCC
GCTGCCGCTGGAGCGCGGGGCGGCAGCGCCATGGCGAGCCCGAAGTCCCCGATGGC
GCATGGCGCACGTGCCGTCGTGGCGCACCAACACGTTCTGACTGCTGAGGTCGCGGT
GCACCACACTGGGCTTGTACAA 
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PS1 - F: 
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PS1 - R: 
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PS2 - F: 
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PS2 - R: 
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PS3b - F: 
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PS3b - R: 
 
 
 
